ES2178634T3 - Peptidos analogos de cnp y su utilizacion. - Google Patents

Peptidos analogos de cnp y su utilizacion.

Info

Publication number
ES2178634T3
ES2178634T3 ES92101621T ES92101621T ES2178634T3 ES 2178634 T3 ES2178634 T3 ES 2178634T3 ES 92101621 T ES92101621 T ES 92101621T ES 92101621 T ES92101621 T ES 92101621T ES 2178634 T3 ES2178634 T3 ES 2178634T3
Authority
ES
Spain
Prior art keywords
ser
arg
gly
phe
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92101621T
Other languages
English (en)
Inventor
Shoji Tanaka
Yoshiharu Minamitake
Yasuo Kitajima
Mayumi Furuya
Hisayuki Matsuo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Suntory Ltd
Original Assignee
Suntory Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suntory Ltd filed Critical Suntory Ltd
Application granted granted Critical
Publication of ES2178634T3 publication Critical patent/ES2178634T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE PRESENTAN NUEVOS PEPTIDOS REPRESENTADOS POR LA FORMULA GENERAL: Y LAS SALES DE ADICION ACIDAS FISIOLOGICAMENTE ACEPTABLES DE LOS MISMOS; DONDE (A) REPRESENTA H-, H-GLY, H-LYS-GLY, H-SER-LYS-GLY, H-LEU-SER-LYS-GLY, H-GLY-LEU-SER-LYS-GLY, H-SER, H-SER-SER, H-ARG-SER-SER, H-ARG-ARG-SER-SER, H-LEU-ARG-ARG-SER-SER, H-SER-LEU-ARG-ARG-SER-SER; (B) REPRESENTA H-CYS O PMP; (C) REPRESENTA PHE-, PC LANDA-PHE, PF-PHE, PNO SUB 2-PHE O CHA; (D) REPRESENTA ILE, VAL, AIB, TLEU, GLY O LEU; (E) REPRESENTA LYS O ARG; (F) REPRESENTA ILE, LEU O MET; (G) REPRESENTA SER O ALA; (H) REPRESENTA MET O GLN; (I) REPRESENTA -OH, -ASN-OH, -ASN-SER-OH, -ASN-SER-PHE-OH, -ASN-SER-PHE-ARG -OH O -ASN-SER-PHE-ARG-TYR-OH; Y EL SIMBOLO "..." REPRESENTA UN ENLACE DE DIFULSURO; SIEMPRE Y CUANDO 1) ALFA-HANP, 2) ALFA-HANP (7-28) Y 3) CNP-22 SEAN EXCLUIDOS DEL ALCANCE DE ESA FORMULA GENERAL. TAMBIEN SE PRESENTAN LOS AGENTES SUPRESORES DEL CRECIMIENTO DE LAS CELULAS MUSCULARES SUAVES VASCULARES QUE CONTIENEN ESOS PEPTIDOS COMO INGREDIENTES EFECTIVOS.
ES92101621T 1991-01-31 1992-01-31 Peptidos analogos de cnp y su utilizacion. Expired - Lifetime ES2178634T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP1132191 1991-01-31
JP3254066A JP2809533B2 (ja) 1991-01-31 1991-06-28 Ｃｎｐ類似体ペプチド

Publications (1)

Publication Number Publication Date
ES2178634T3 true ES2178634T3 (es) 2003-01-01

Family

ID=26346733

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92101621T Expired - Lifetime ES2178634T3 (es) 1991-01-31 1992-01-31 Peptidos analogos de cnp y su utilizacion.

Country Status (6)

Country Link
US (1) US5434133A (es)
EP (1) EP0497368B1 (es)
JP (1) JP2809533B2 (es)
AT (1) ATE219103T1 (es)
DE (1) DE69232636T2 (es)
ES (1) ES2178634T3 (es)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994020534A1 (en) * 1993-03-03 1994-09-15 Mayo Foundation For Medical Education And Research Vasonatrin peptide and analogs thereof
US6525022B1 (en) 1993-11-12 2003-02-25 Genentech, Inc. Receptor specific atrial natriuretic peptides
US5846932A (en) * 1993-11-12 1998-12-08 Genentech, Inc. Receptor specific atrial natriuretic peptides
US5665704A (en) * 1993-11-12 1997-09-09 Genentech, Inc. Receptor specific atrial natriuretic peptides
WO2000018422A1 (fr) * 1998-09-28 2000-04-06 Santen Pharmaceutical Co., Ltd. Promoteurs de secretion lacrymale ou gouttes ophtalmologiques contenant des peptides natriuretiques comme principes actifs pour traiter la keratoconjonctivite
DE19903087A1 (de) * 1999-01-27 2000-08-10 Forssmann Wolf Georg Behandlung von erektilen Dysfunktionen mit C-Typ Natriuretischem Polypeptid (CNP) als Monotherapie oder in Kombination mit Phosphodiesterasehemmern
IL142118A0 (en) * 2001-03-20 2002-03-10 Prochon Biotech Ltd Method and composition for treatment of skeletal dysplasias
BRPI0203172B8 (pt) 2001-09-28 2021-05-25 Nakao Kazuwa composição farmacêutica para acondroplasia
JP5503837B2 (ja) * 2003-03-26 2014-05-28 ポール，サッドヒル 非共有結合により誘導される求核性タンパク質へのリガンドの共有結合
WO2005000095A2 (en) * 2003-06-20 2005-01-06 Mayo Foundation For Medical Education And Research Isoforms of brain natriuretic peptide
ES2465141T3 (es) 2004-03-31 2014-06-05 Kazuwa Nakao Remedio o medicamento preventivo para la artritis
WO2005094890A1 (ja) 2004-03-31 2005-10-13 Kazuwa Nakao 身長増加用組成物
CA2559228C (en) 2004-04-21 2016-06-21 Enobia Pharma Inc. Bone delivery conjugates and method of using same to target proteins to bone
CA2647143A1 (en) 2006-03-30 2007-10-11 Palatin Technologies, Inc. Cyclic natriuretic peptide constructs
EP2004633A4 (en) 2006-03-30 2009-08-26 Palatin Technologies Inc LINEAR NATRIURETIC PEPTIDE CONSTRUCTS
US8580746B2 (en) 2006-03-30 2013-11-12 Palatin Technologies, Inc. Amide linkage cyclic natriuretic peptide constructs
CN101501067B (zh) * 2006-08-08 2013-01-16 梅约医学教育与研究基金会 利尿和利尿钠的多肽
CN101541957B (zh) * 2007-07-20 2013-08-14 梅约医学教育与研究基金会 利尿钠多肽
WO2009046873A1 (en) * 2007-09-11 2009-04-16 Mondobiotech Laboratories Ag Combined use of vasonatrin and gastrin-i as a therapeutic agent
WO2009036448A2 (en) * 2007-09-15 2009-03-19 Mayo Foundation For Medical Education And Research Natriuretic peptide receptor-c agonists
EP2217620A2 (en) * 2007-11-21 2010-08-18 BioMarin Pharmaceutical Inc. Variants of c-type natriuretic peptide
WO2009086126A2 (en) * 2007-12-21 2009-07-09 Mayo Foundation For Medical Education And Research Natriuretic polypeptides
PT2432489T (pt) * 2009-05-20 2016-12-07 Biomarin Pharm Inc Variantes do péptido natriurético de tipo c
US20120208756A1 (en) 2009-07-23 2012-08-16 Igisu Co., Ltd Composition for external preparation for skin
WO2011024973A1 (ja) * 2009-08-27 2011-03-03 株式会社 イギス 鼻炎治療剤
WO2012013597A1 (de) * 2010-07-28 2012-02-02 Justus-Liebig-Universität Giessen Stoffe und deren verwendung zur beeinflussung natriuretischer peptidrezeptoren
WO2012088608A1 (en) 2010-12-27 2012-07-05 Enobia Canada Limited Partnership Compositions comprising natriuretic peptides and methods of use thereof
MX353295B (es) 2011-01-21 2018-01-08 Endo Kyoko Agente para el tratamiento de la alopecia.
WO2012118042A1 (ja) * 2011-02-28 2012-09-07 独立行政法人国立循環器病研究センター 悪性腫瘍転移抑制用医薬
CN103906761B (zh) 2011-08-30 2016-12-21 梅约医学教育与研究基金会 利钠多肽
KR20140084201A (ko) 2011-10-19 2014-07-04 알렉시온 파마 홀딩 알칼리성 포스파타제 및/또는 나트륨이뇨 펩티드를 포함하는 조성물 및 그의 사용 방법
WO2013103896A1 (en) 2012-01-06 2013-07-11 Mayo Foundation For Medical Education And Research Treating cardiovascular or renal diseases
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
CN104059154B (zh) * 2014-05-06 2017-09-29 中国人民解放军第四军医大学 一种新的具有抗心力衰竭作用的钠尿肽嵌合体cnaac
WO2016007873A1 (en) 2014-07-11 2016-01-14 The Regents Of The University Of Michigan Compositions and methods for treating craniosynostosis
MX389350B (es) 2014-12-05 2025-03-19 Alexion Pharma Inc Fosfatasas alcalinas recombinantes y usos de las mismas para el tratamiento de convulsiones.
JP6868561B2 (ja) 2015-01-28 2021-05-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼ欠損を有する被験者を治療する方法
DK3328416T5 (da) 2015-07-30 2024-10-07 Biomarin Pharm Inc Anvendelse af natriuretske peptidvarianter af c-typen til behandling af skeletdysplasi
JP7253220B2 (ja) * 2015-07-31 2023-04-06 株式会社 イギス Ｃｎｐ環状ペプチド並びに該環状ペプチドを含む医薬品、外用剤および化粧料
CN108350440A (zh) 2015-08-17 2018-07-31 阿雷克森制药公司 碱性磷酸酯的制造
JP6868617B2 (ja) 2015-09-28 2021-05-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド 低ホスファターゼ血症の組織非特異的アルカリホスファターゼ（ｔｎｓａｌｐ）酵素補充療法に有効な投薬計画の特定
JP2018533571A (ja) 2015-10-30 2018-11-15 アレクシオン ファーマシューティカルズ， インコーポレイテッド 患者の頭蓋縫合早期癒合症を治療するための方法
HUE057083T2 (hu) 2015-12-08 2022-04-28 Biomarin Pharm Inc C-típusú nátriuretikus peptid változatainak alkalmazása oszteoartritisz kezelésére
WO2017155569A1 (en) 2016-03-08 2017-09-14 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children
US10898549B2 (en) 2016-04-01 2021-01-26 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
JP7613826B2 (ja) 2016-04-01 2025-01-15 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼによって筋力低下を治療すること
US10988744B2 (en) 2016-06-06 2021-04-27 Alexion Pharmaceuticals, Inc. Method of producing alkaline phosphatase
EP3500289B1 (en) 2016-08-18 2024-10-09 Alexion Pharmaceuticals, Inc. Asfotase alfa for use in treating tracheobronchomalacia
EP3600383A4 (en) 2017-03-31 2020-10-28 Alexion Pharmaceuticals, Inc. METHODS OF TREATMENT OF HYPOPHOSPHATASIA (HPP) IN ADULTS AND ADOLESCENTS
US11913039B2 (en) 2018-03-30 2024-02-27 Alexion Pharmaceuticals, Inc. Method for producing recombinant alkaline phosphatase
US12268733B2 (en) 2018-08-10 2025-04-08 Alexion Pharmaceuticals, Inc. Methods of treating neurofibromatosis type 1 and related conditions with alkaline phosphatase
CA3161266A1 (en) 2019-12-09 2021-06-17 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof
AU2021337652B2 (en) 2020-09-04 2025-01-30 Alexion Pharmaceuticals, Inc. Methods for treating bone mineralization disorders
BR112023016048A2 (pt) 2021-02-12 2023-11-14 Alexion Pharma Inc Polipeptídeos de fosfatase alcalina e métodos de uso dos mesmos
WO2024086680A2 (en) 2022-10-21 2024-04-25 Eli Lilly And Company Long-acting natriuretic peptides and uses thereof
WO2024094747A1 (en) 2022-11-02 2024-05-10 Novo Nordisk A/S Cnp compounds

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4496544A (en) * 1983-11-10 1985-01-29 Washington University Atrial Peptides
JPH0672157B2 (ja) * 1984-08-29 1994-09-14 味の素株式会社 新規ペプチド
EP0232078A3 (en) * 1986-01-31 1990-03-14 Merck & Co. Inc. Peptides having anf activity
EP0292256A3 (en) * 1987-05-19 1990-10-03 Merck & Co. Inc. Peptides having anf activity
US4935492A (en) * 1987-12-24 1990-06-19 California Biotechnology Inc. Cyclic analogs of atrial natriuretic peptides
CA1339210C (en) * 1988-05-31 1997-08-05 John Lewicki Recombinant techniques for production of novel natriuretic and vasodilator peptides
DK380288D0 (da) * 1988-07-07 1988-07-07 Novo Industri As Hidtil ukendet peptider
ES2073751T3 (es) * 1990-04-20 1995-08-16 Hisayuki Matsuo Nuevo peptido con actividad fisiologica de origen porcino.
JP2801079B2 (ja) * 1990-11-14 1998-09-21 サントリー株式会社 Ａｎｐ関連新規ペプチド

Also Published As

Publication number Publication date
JPH069688A (ja) 1994-01-18
EP0497368A1 (en) 1992-08-05
US5434133A (en) 1995-07-18
DE69232636D1 (de) 2002-07-18
ATE219103T1 (de) 2002-06-15
JP2809533B2 (ja) 1998-10-08
DE69232636T2 (de) 2002-12-05
EP0497368B1 (en) 2002-06-12

Similar Documents

Publication Publication Date Title
ES2178634T3 (es) Peptidos analogos de cnp y su utilizacion.
CO4750841A1 (es) Compuestos ciclicos, inhibidores de la adhesion
ES2070322T3 (es) Polipeptidos biologicamente activos basados en las secuencias del factor de crecimiento de transformacion beta.
ES2054017T3 (es) Metodo para combatir pneumocystis carinii.
ES2071292T3 (es) Soluciones inyectables estables de factor viii.
NO905472L (no) Insulinanaloger fra menneske og blandinger som inneholderdem.
ES2054842T3 (es) Analogo del factor viii, procedimiento de preparacion y composicion farmaceutica que lo contiene.
CY1110927T1 (el) Αμινο-καταληκτικως διακλαδισμενη rantεs ως ανταγωνιστης των χημοκινων
NL300013I1 (nl) Nieuwe protein met TNF-remmende werking en hun ber
ES2151699T3 (es) Hilo endovascular electroliticamente separable para la formacion de trombos.
KR930009591A (ko) 트리-아르기닌 인슐린
ES2137182T3 (es) Derivados recombinantes del factor viii humano.
DE69021335D1 (de) Wachstumshormonfusionsproteine.
ES2140436T3 (es) Esteroides de 17-espirometileno.
DK0466175T3 (da) Porcint CNP-gen og præcursor-protein
ES2107033T3 (es) Peptidos bpc, su preparacion y su utilizacion.
DE69230418D1 (de) GRF-Analoge (Growth Hormone Releasing Factors)
ES8606490A1 (es) Un derivado de polipeptido de interferon-a humano
NZ224914A (en) Tissue plasminogen activator analog
ES2056753A6 (es) Un procedimiento para la produccion de un polipeptido que tiene actividad de factor quemotactico de monocitos humanos.
AR241800A1 (es) Procedimiento para preparar compuestos de eglina y procedimiento para obtener preparados farmaceuticos que incluyan a dichos compuestos de eglina como agente activo.
AU682638B2 (en) Peptide, bronchodilator and blood flow ameliorant
EP0292257A3 (en) Peptides having anf activity
ES2076933T3 (es) Nuevos sustratos peptidicos.
ES2051939T3 (es) Heteroaromatos fenoxialquilsubstituidos, procedimientos para su obtencion y su empleo para la lucha contra las pestes.